PELI3: A promising drug target and biomarker for the treatment of cancer

Target Name: PELI3

NCBI ID: G246330

PELI3

PELI3: A promising drug target and biomarker for the treatment of cancer

Abstract:

Pellino E3 ubiquitin protein ligase family member 3 (PELI3) is a protein that plays a crucial role in the regulation of protein stability and degradation. PELI3 has been identified as a potential drug target and biomarker for the treatment of cancer. This article aims to provide an overview of PELI3, its functions, and potential as a drug target.

Introduction:

Pellino E3 ubiquitin protein ligase family member 3 (PELI3) is a protein that is expressed in various tissues and cells, including the brain, eye, and gastrointestinal tract. PELI3 is a member of the Pellino E3 ubiquitin protein ligase family, which is a group of enzymes that play a central role in the regulation of protein stability and degradation.

PELI3 functions as a protein that can add the ubiquitin molecule to the protein target, which can modulate the stability and localization of the target protein. PELI3 is also involved in the degradation of some proteins, including the neuron-specific protein PSMA-2.

PELI3 as a drug target:

PELI3 has been identified as a potential drug target for the treatment of cancer due to its involvement in the regulation of protein stability and degradation. Cancer cells have an increased demand for protein stability and degradation, which allows them to evade the effects of anti-cancer drugs. By targeting PELI3, researchers can disrupt the stability and localization of cancer proteins, leading to the inhibition of their functions and the regression of cancer growth.

PELI3 as a biomarker:

PELI3 can also be used as a biomarker for the diagnosis and monitoring of cancer. Since PELI3 is expressed in various tissues and cells, its levels can be used as a marker for the presence of cancer cells. Additionally, changes in PELI3 levels can also be used as an indicator of disease progression and response to anti-cancer treatments.

PELI3 inhibition in cancer cells:

Several studies have shown that inhibiting PELI3 can lead to the inhibition of the functions of cancer proteins. For example, experiments have shown that inhibition of PELI3 can lead to the inhibition of the migration and invasion of cancer cells. Additionally, PELI3 inhibition has also been shown to inhibit the formation of new blood vessels, which can contribute to tumor growth.

PELI3 inhibition in human models:

Preclinical studies have also shown that PELI3 inhibition can be effective in inhibiting the growth of human cancer cells in a xenograft model. In addition, animal models of cancer have also shown that PELI3 inhibition can be effective in inhibiting the growth and metastasis of cancer cells.

Conclusion:

Pellino E3 ubiquitin protein ligase family member 3 (PELI3) is a protein that plays a crucial role in the regulation of protein stability and degradation. PELI3 has been identified as a potential drug target and biomarker for the treatment of cancer. In addition, PELI3 inhibition has been shown to inhibit the functions of cancer proteins and can be used as a biomarker for the diagnosis and monitoring of cancer. Further research is needed to fully understand the role of PELI3 in cancer treatment and to develop effective strategies for its targeting.

Protein Name: Pellino E3 Ubiquitin Protein Ligase Family Member 3

Functions: E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates 'Lys-63'-linked polyubiquitination of IRAK1. Can activate AP1/JUN and ELK1. Not required for NF-kappa-B activation

The "PELI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PELI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets